Humana jumps 6.3% as investors revisit Medicare Advantage margin outlook after recent guidance and policy updates

Humana Inc. (HUM) is up 6.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a renewed “managed care relief” narrative, as investors continue to price in improving reimbursement conditions for Medicare Advantage and greater visibility into Humana’s multi-year margin recovery plan. With the company having recently affirmed its full-year outlook, the stock can also react sharply to incremental shifts in sentiment (including short covering) even without a single headline.

Details:

Humana’s most recent quarterly update reaffirmed full-year 2026 adjusted EPS guidance of at least $9.00, helping anchor expectations after a volatile period for Medicare Advantage profitability.

In April, federal Medicare Advantage rate-setting for 2027 finalized a higher net payment update than initially proposed, which broadly supported insurers with heavy Medicare Advantage exposure.

Humana’s business is highly sensitive to reimbursement and risk-adjustment assumptions, so even small perceived improvements in future bid-year economics can drive outsized stock moves.

Short interest has been elevated versus typical defensive mega-cap healthcare levels, which can amplify rallies when the tape turns positive.

Sources:

Humana Investor Relations, Centers for Medicare & Medicaid Services, S&P Global Market Intelligence

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$HUM Insider Trading Activity

$HUM insiders have traded $HUM stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $HUM stock by insiders over the last 6 months:

SANJAY K SHETTY (President, CenterWell) purchased 810 shares for an estimated $150,016

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive HUM Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$HUM Hedge Fund Activity

We have seen 298 institutional investors add shares of $HUM stock to their portfolio, and 566 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 3,514,521 shares (-74.8%) from their portfolio in Q4 2025, for an estimated $900,174,263
CAPITAL INTERNATIONAL INVESTORS added 3,097,571 shares (+113.9%) to their portfolio in Q4 2025, for an estimated $793,380,860
BANK OF NEW YORK MELLON CORP removed 1,479,679 shares (-70.6%) from their portfolio in Q1 2026, for an estimated $256,561,541
PZENA INVESTMENT MANAGEMENT LLC added 1,398,774 shares (+34.3%) to their portfolio in Q1 2026, for an estimated $242,533,423
WELLINGTON MANAGEMENT GROUP LLP added 1,170,387 shares (+4481.7%) to their portfolio in Q4 2025, for an estimated $299,771,222
FRANKLIN RESOURCES INC added 1,131,893 shares (+914.5%) to their portfolio in Q4 2025, for an estimated $289,911,754
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 1,008,514 shares (+28.9%) to their portfolio in Q4 2025, for an estimated $258,310,690

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$HUM Congressional Stock Trading

Members of Congress have traded $HUM stock 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $HUM stock by members of Congress over the last 6 months:

REPRESENTATIVE JULIA LETLOW sold up to $15,000 on 02/10.
REPRESENTATIVE GILBERT RAY CISNEROS, JR. sold up to $15,000 on 11/12.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$HUM Analyst Ratings

Wall Street analysts have issued reports on $HUM in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Guggenheim issued a "Buy" rating on 04/30/2026
Jefferies issued a "Buy" rating on 12/05/2025

To track analyst ratings and price targets for $HUM, check out Quiver Quantitative's $HUM forecast page.

$HUM Price Targets

Multiple analysts have issued price targets for $HUM recently. We have seen 13 analysts offer price targets for $HUM in the last 6 months, with a median target of $227.0.

Here are some recent targets:

Lisa Gill from JP Morgan set a target price of $214.0 on 05/01/2026
Ryan Langston from TD Cowen set a target price of $211.0 on 05/01/2026
David Macdonald from Truist Securities set a target price of $270.0 on 04/30/2026
Jason Cassorla from Guggenheim set a target price of $269.0 on 04/30/2026
Andrew Mok from Barclays set a target price of $180.0 on 04/30/2026
Elizabeth Suzuki from Evercore ISI Group set a target price of $250.0 on 04/30/2026
Ben Hendrix from RBC Capital set a target price of $246.0 on 04/30/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.